INTROGEN RECEIVES LICENSE FOR CHINESE PATENT

Introgen Therapeutics Inc. says China issued a patent to the University of Texas for various genetic combination therapies used with the p53 gene and conventional chemotherapy or radiation. The patent is licensed to Introgen through an agreement with UT in Austin and the M.D. Anderson Cancer Center in Houston. David Parker, Introgen's senior vice president of intellectual property, says: "Strategically, this is an important patent that further complements our existing international patent portfolio. This development augments our goal to address significant populations of cancer patients receiving radiation or chemotherapy treatments, who may also be candidates for p53 therapy."

Austin Business Journal (http://austin.bizjournals.com/austin/stories/2005/08/08/daily11.html)